Testing gedatolisib plus darolutamide in advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of two drugs, gedatolisib and darolutamide, in men with prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can help control the cancer when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man 18 or older.
- You have prostate cancer that has spread to other parts of the body and is growing despite hormone therapy.
- You have already tried one newer hormone therapy (like enzalutamide or abiraterone) and it stopped working.
- You have not had chemotherapy or a radiopharmaceutical for your metastatic cancer before (except docetaxel with hormone therapy for early stage).
- You are healthy enough to be up and about (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding darolutamide and degarelix to radiation can improve outcomes in men with intermediate-risk prostate cancer. If you fit the cancer and health criteria, it may offer a way to treat the cancer more aggressively than radiation alone.
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
Hear when a new Genital Diseases, Male trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.